Does growth hormone therapy increase the risk of cancer?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 10, 2006, Pages 530-531

  Swerdlow, Anthony J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; GROWTH HORMONE; HUMAN GROWTH HORMONE; MITOGENIC AGENT; SOMATOMEDIN C;

ACROMEGALY; BREAST CANCER; CANCER RISK; COLORECTAL CANCER; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

ANIMALS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 33749551108     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0295     Document Type: Short Survey

References (10)

1. Swerdlow AJ et al. (2002) Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-1985: a cohort study. Lancet 360: 273-277
2. Fradkin JE et al. (1993) Risk of leukemia after treatment with pituitary growth hormone. JAMA 270: 2829-2832
3. Mills JL et al. (2004) Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 144: 430-436
4. Sklar CA et al. (2002) Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 87: 3136-3141
5. Nishi Y et al. (1999) Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. J Clin Endocrinol Metab 84: 1961-1965
6. Svensson J et al. (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89: 3306-3312
7. Kemp SF et al. (2005) Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 90: 5247-5253
8. Tuffli GA et al. (1995) Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab 80: 1416-1422
9. Allen DB et al. (1997) Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 131: S32-S36
10. Swerdlow AJ (2000) Design and interpretation of studies of the risk of cancer and other long-term morbidity and mortality after growth hormone treatment. Growth Horm IGF Res 10: 318-323